Detalhe da pesquisa
1.
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.
Bioconjug Chem
; 35(2): 140-146, 2024 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38265691
2.
Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.
Bioorg Med Chem Lett
; 25(17): 3582-4, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26164189
3.
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Bioorg Med Chem Lett
; 25(17): 3575-81, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26199119
4.
Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Bioorg Med Chem Lett
; 25(17): 3569-74, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26206504
5.
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
J Med Chem
; 65(12): 8345-8379, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35500094
6.
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Cancer Discov
; 12(6): 1500-1517, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404998
7.
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.
J Med Chem
; 65(24): 16173-16203, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399068
8.
Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
BMC Cancer
; 11: 24, 2011 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21247487
9.
EndoBind detects endogenous protein-protein interactions in real time.
Commun Biol
; 4(1): 1085, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34526658
10.
A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays.
Leuk Lymphoma
; 61(13): 3052-3065, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32799592
11.
Modulation of drug resistance by artificial transcription factors.
Mol Cancer Ther
; 7(3): 688-97, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18319335
12.
New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.
ACS Med Chem Lett
; 10(12): 1655-1660, 2019 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857842
13.
Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.
Cancer Chemother Pharmacol
; 80(4): 869-878, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28779265
14.
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
ACS Med Chem Lett
; 7(8): 735-40, 2016 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27563395
15.
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Cancer Res
; 76(2): 390-402, 2016 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26577700
16.
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Elife
; 42015 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25965177
17.
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Mol Cancer Ther
; 13(5): 1117-29, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24608574
18.
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Mol Cancer Ther
; 11(2): 317-28, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22188813
19.
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Mol Cancer Ther
; 11(8): 1747-57, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22653967
20.
Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Elife
; 52016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27852439